Core Viewpoint - Opus Genetics, Inc. is urging stockholders to vote for its nine nominated directors on the BLUE proxy card, emphasizing the importance of the upcoming Annual Meeting on April 30, 2025, as a pivotal moment for the company's transformation and future success [2][3][15] Company Strategy and Transformation - The company has undergone significant changes over the past two years, including a strategic repositioning after facing challenges with its previous assets [4][5] - In April 2023, the board terminated the former CEO, Mina Sooch, and appointed Dr. George Magrath as the new CEO to lead the company towards long-term growth [5][6] - The new management team, supported by an independent consulting firm, evaluated over 50 potential assets and identified a compelling pipeline of gene therapies for inherited retinal diseases from Legacy Opus [6][7][8] Recent Developments - In October 2024, Ocuphire announced the acquisition of Legacy Opus, adopting the name Opus Genetics to reflect its new strategy [9] - The company is seeking stockholder approval for the conversion of preferred shares into common shares to align interests and advance its new plan [9] Board of Directors and Leadership - The board has strengthened its composition by appointing three new directors with significant experience in biotechnology and clinical development, alongside six other nominees who have contributed to the company's transformation [10][11] - The board emphasizes the qualifications and dedication of its nominees, who possess expertise in critical areas for the company's success [11] Financial Support and Investor Confidence - The company recently completed a public offering and private placement, raising $21.5 million from prominent healthcare investors, indicating strong support for its new strategy and leadership [12] Opposition and Challenges - Former CEO Mina Sooch has nominated herself and five associates to replace a majority of the board, which the current board believes would not serve the best interests of stockholders [13][14] - The board argues that Sooch's proposed strategy is flawed and would hinder the company's progress, advocating instead for the continuation of the current gene therapy-focused strategy [14][15]

Core Viewpoint - Opus Genetics, Inc. is urging stockholders to vote for its nine nominated directors on the BLUE proxy card, emphasizing the importance of the upcoming Annual Meeting on April 30, 2025, as a pivotal moment for the company's transformation and future success [2][3][15] Company Strategy and Transformation - The company has undergone significant changes over the past two years, including a strategic repositioning after facing challenges with its previous assets [4][5] - In 2023, the board terminated the former CEO and appointed Dr. George Magrath as the new CEO, who has since built a strong executive team [5][11] - A review of the company's assets led to the acquisition of Legacy Opus, which has a promising pipeline of gene therapies for inherited retinal diseases [6][9] Board of Directors and Governance - The board is nominating nine candidates for election, including three new directors with extensive experience in biotechnology and clinical development [10][11] - The board believes that the election of the former CEO's nominees would not serve the best interests of stockholders and could reverse the company's progress [13][14] Financial Support and Market Confidence - The company recently raised $21.5 million from top-tier healthcare investors, indicating strong market confidence in its new strategy and leadership [12]